Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017


Posted on: 03 Oct 17

BOSTON, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced data from its completed Phase 2 study of lead product candidate A4250 in children with cholestatic liver disease will be presented during a poster session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2017, being held October 20-24, 2017, at the Walter E. Washington Convention Center in Washington, D.C.

Details of the presentation are as follows:

Title: The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple-dose, open-label, multinational study (Abstract #1200)
Session: Poster Session II
Date/Time: October 21, 2017, from 5:30 to 7:00 p.m. ET
Location: Walter E. Washington Convention Center, Hall D
Presenter: Dr. Ekkehard Sturm, Head of Pediatric Gastroenterology and Hepatology, University Hospital Tuebingen, Germany

Abstracts for the meeting can be viewed in the October issue of HEPATOLOGY.

The Liver Meeting®, the 68th Annual Meeting of the AASLD, brings together more than 9,500 physicians, researchers and health professionals from around the world to discuss and advance the science and practice of hepatology. For more information about the meeting, visit: www.aasld.org/events-professional-development/liver-meeting.

About Albireo 
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:
Hans Vitzthum                                    
LifeSci Advisors, LLC.                       
212-915-2568                                     

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com   

GlobeNewswire
globenewswire.com

Last updated on: 04/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.